Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
A tumor registry studies the genetics of pancreatic cancer to determine risk factors for families.
Elizabeth Pršić describes her mother Andrea’s pancreatic cancer treatment. Andrea has the BRCA2 mutation, which helps determine the plan.
David Dessert explains that his aunt’s genetic testing for BRCA2 mutation directed his own treatment for pancreatic cancer.
Sharon Seibel knew she had the BRCA2 mutation but was unaware of the link to pancreatic cancer. Her chemotherapy was one for BRCA carriers.